The positive effect of JAK inhibitor tofacitinib in the treatment of primary Sjögren’s syndrome: a clinical case

The positive effect of JAK inhibitor tofacitinib in the treatment of primary Sjögren’s syndrome: a clinical case

Primary Sjögren’s syndrome (pSS, Sjögren’s disease) is a systemic autoimmune disease which develops in previously healthy individuals and characterized by damage to exocrine glands, mainly lacrimal and salivary glands, with gradual formation of their secretory insufficiency and various systemic mani...

Full description

Bibliographic Details
Main Authors:	D.G. Rekalov, I.O. Daniuk
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2023-03-01
Series:	Bolʹ, Sustavy, Pozvonočnik
Subjects:	primary sjögren’s syndrome janus kinase inhibitor tofacitinib clinical case
Online Access:	https://pjs.zaslavsky.com.ua/index.php/journal/article/view/357

Similar Items

Glucocorticoids combined with tofacitinib for systemic sarcoidosis with rash as initial symptom: a case report
by: Hu Rongrong, Hong Yixin, Su Xiangyang, Ma Guiyan, Chen Peiran
Published: (2023-05-01)

Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
by: Sara Sadeghi, et al.
Published: (2022-10-01)

Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib
by: Ji Su Lee, et al.
Published: (2018-11-01)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
by: Junmei Zhang, et al.
Published: (2023-10-01)

User's guide to JAK inhibitors in inflammatory bowel disease
by: Ted A. Spiewak, DO, et al.
Published: (2022-01-01)

Two cases of bullous pemphigoid effectively treated with oral tofacitinib
by: Soundos Youssef, MD, et al.
Published: (2023-02-01)

Tofacitinib in the treatment of primary Sjögren’s syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial
by: Ronglin Gao, et al.
Published: (2023-11-01)

The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
by: Diqin Yan, et al.
Published: (2022-08-01)

Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
by: Marino Paroli, et al.
Published: (2023-08-01)

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib
by: Carolina Neudorfer, MD, et al.
Published: (2023-09-01)

Oral tofacitinib citrate for recalcitrant cutaneous lupus
by: Evelyne Bonnardeaux, MD, et al.
Published: (2022-02-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream
by: Shannon Nugent, BS, et al.
Published: (2022-11-01)

Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
by: Luo N, et al.
Published: (2023-05-01)

Clinical response to oral tofacitinib in pediatric patients with alopecia areata
by: Soundos Youssef, MD, et al.
Published: (2023-01-01)

Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
by: Adriana Coricello, et al.
Published: (2020-07-01)

Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
by: Manuel Morgado, et al.
Published: (2017-04-01)

Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation
by: O. V. Knyazev, et al.
Published: (2021-10-01)

JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells
by: Yuya Fujita, et al.
Published: (2020-06-01)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
by: Jacopo Angelini, et al.
Published: (2020-07-01)

Tofacitinib
by: Nilgün Şentürk
Published: (2022-04-01)

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
by: Michael V. Chiorean, et al.
Published: (2022-04-01)

Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease
by: Wang CR, et al.
Published: (2023-12-01)

JAK inhibitors in rheumatology
by: Kunihiro Yamaoka, et al.
Published: (2023-07-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

VEXAS syndrome presenting as refractory cutaneous Kikuchi disease-like inflammatory pattern responding to tofacitinib
by: Lauren M. Fahmy, BS, et al.
Published: (2023-08-01)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
by: Maria Pia Adorni, et al.
Published: (2023-08-01)

Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis
by: Kevin Phan, et al.
Published: (2022-01-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
by: G. V. Lukina, et al.
Published: (2015-12-01)

Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis
by: Yu. S. Kovaleva, et al.
Published: (2022-03-01)

Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report
by: Stéphanie Dierckx, et al.
Published: (2024-02-01)

Case Report: Morbihan disease treated with tofacitinib successfully
by: Zi-Yun Li, et al.
Published: (2023-06-01)

Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
by: Aniseh Samadi, et al.
Published: (2017-08-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

JAK-inhibitors in dermatology: current evidence and future applications
by: Piotr Ciechanowicz, et al.
Published: (2019-10-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
by: Robert Harrington, et al.
Published: (2023-10-01)

Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
by: Zong Jiang, et al.
Published: (2023-06-01)

Seronegative primary Sjögren’s syndrome, a distinct subtype of primary Sjögren’s syndrome in Chinese patients
by: Jingying Lan, et al.
Published: (2024-04-01)

JAK inhibitors ∼ overview∼
by: Hideto Kameda
Published: (2023-07-01)